ArticleCardiovascular and interventional radiology2026
Initial Experience with Transarterial Chemoembolization in Metastatic Cutaneous Melanoma Patients with Hepatic Progression on Immune Checkpoint Inhibitors.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the safety and efficacy of performing degradable starch microspheres transarterial chemoembolization (DSM-TACE) in metastatic melanoma (MM) patients with progressive liver metastases following immune checkpoint inhibitors (ICI) treatment. MATERIAL AND
methodsThis case series evaluates 10 adult patients with MM who exhibited hepatic progression after an initial response to ICI therapy and underwent DSM-TACE without discontinuation of systemic checkpoint inhibitor therapy from January 2023 to September 2024. Tumor response was assessed using RECIST 1.1 criteria. The primary outcome measure of the study was the best overall response rate. Secondary outcome measures included local tumor control, progression-free survival, and overall survival. Adverse events were monitored and recorded.
resultsTen melanoma patients (median age: 69.5 years; six females) who underwent DSM-TACE due to hepatic progression following an initial response to ICI therapy were included for safety analysis. Imaging data were unavailable for two patients, who were therefore excluded from further analyses. Best overall response rate was 87.5% (CR in two patients, PR in five patients, and SD in one patient). All treated lesions displayed sustained local tumor control throughout the follow-up. Six patients (75%) experienced the occurrence of new intra- or extrahepatic metastases. The median PFS was 8.5 months. Median OS was 12 months. Severe or life-threatening (grade 3-4) AEs associated with the combined treatment were reported in 40% (4/10-pseudoaneurysm at the puncture side, immune-related pancreatitis, anthracnosis, and colitis). Cocnclusion. Incorporating locoregional therapies, such as DSM-TACE, in patients with liver metastases from cutaneous melanoma undergoing ICI treatment is feasible, safe, and effective in achieving local disease control, potentially extending PFS and OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.